Page 306 - ATP-P 11th Ed

th
• 4 generation: Same as 3 generation plus coverage against Pseudomonas.
rd
° Example: cefepime
Cerebyx – See Fosphenytoin
®
Chloroquine Phosphate
Indications: Malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of P.
falciparum.
Dose: The dosage of chloroquine phosphate is often expressed in terms of equivalent
chloroquine base. Each 500mg tablet of chloroquine phosphate contains the equivalent of
300mg chloroquine base.
Adult dose:
• Prophylaxis: 500mg (= 300mg base) on the same day of each week. Initiate therapy 1 to
2 weeks prior to departure to endemic area
• Dose must be administered on same day of week
SECTION 3 • Treatment: 1g PO × 1 then 500mg PO daily × 3 days starting 6 hours after first dose
• Continue prophylaxis for 4 additional weeks upon return from endemic area
Pediatric dose: The weekly suppressive dosage is 5mg calculated as base, per kg of body
weight, but should not exceed the adult dose regardless of weight.
• Precautions: Liver disease, blood disorders, psoriasis, a certain metabolic disease
(glucose-6-phosphate dehydrogenase-G6PD deficiency), hearing problems, seizures.
Contraindications: Known allergy to medication
Pregnancy Category C – Generally accepted as safe
Side-effects
• Nausea
• Vomiting
• Stomach upset
• Cramps
• Loss of appetite
• Diarrhea
• Blurred vision
• Trouble seeing at night or problems focusing clearly
• Easy bleeding or bruising
Warnings:
° It has been found that certain strains of P. falciparum have become resistant to chloro-
quine and hydroxychloroquine. Chloroquine resistance is widespread and, at present,
is particularly prominent in various parts of the world including sub-Saharan Africa,
Southeast Asia, the Indian subcontinent, and over large portions of South America,
including the Amazon basin. 1

296 SECTION 3 RECOMMENDED DRUG LIST (RDL)